AcuCort

The study titled "Swedish Allergists' View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions" was conducted in 2023. The study was carried out through interviews with clinically experienced allergists.

The primary objective of the study was to clarify when and to what extent cortisone is used in relation to the severity of allergies and the treatment conditions in acute situations for patients currently treated with cortisone tablets.

According to the allergists in the study, cortisone is primarily used for severe acute symptoms, where cortisone is a main option, as well as an adjunctive treatment (together with adrenaline and antihistamine) in anaphylaxis. Four out of five allergists considered the treatment situation to be often suboptimal, as patients are either alone, stressed, and/or have forgotten to bring the medication or water. Since Zeqmelit® has properties that facilitate administration and compliance, all the allergists in the study saw clear advantages with Zeqmelit® compared to cortisone tablets.
 

– Previous studies show that patients prefer self-dissolving oral films over tablets. The fact that allergists with clinical experience also see the benefits is something we look forward to presenting at ISPOR in Barcelona, says AcuCort's CEO, Jonas Jönmark.

The study will be presented on November 19, 2024, between 4:00 PM – 7:00 PM, with a discussion of the results taking place from 6:00 PM – 7:00 PM.

Read more about ISPOR here: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2024

For further information: 
Jonas Jönmark, vd, AcuCort AB
Tel: +46 70 365 5400
Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.